Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer

被引:0
作者
Duan, Lei [1 ]
Calhoun, Sarah J. [1 ]
Perez, Ricardo E. [1 ]
Macias, Virgilia [2 ]
Mir, Fatima [3 ]
Gattuso, Paolo [3 ]
Maki, Carl G. [1 ]
机构
[1] Rush Univ, Dept Anat & Cell Biol, Med Ctr, 1705 W Harrison St,Jelke Bldg R1306, Chicago, IL 60612 USA
[2] Univ Illinois, Dept Pathol, Chicago, IL 60612 USA
[3] Rush Univ, Dept Pathol, Med Ctr, Chicago, IL 60612 USA
关键词
PRCP; IGF1R; HER3; endocrine therapy; prognosis; POSTMENOPAUSAL WOMEN; TAMOXIFEN RESPONSE; RESISTANCE; EXPRESSION; ERBB3; ACTIVATION; GROWTH; CELLS;
D O I
10.1080/15384047.2022.2142008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prolylcarboxypeptidase (PRCP) is a lysosomal serine protease that cleaves peptide substrates when the penultimate amino acid is proline. Previous studies have linked PRCP to blood-pressure and appetite control through its ability to cleave peptide substrates such as angiotensin II and alpha-MSH. A potential role for PRCP in cancer has to date not been widely appreciated. Endocrine therapy resistance in breast cancer is an enduring clinical problem mediated in part by aberrant receptor tyrosine kinase (RTK) signaling. We previously found PRCP overexpression promoted 4-hydroxytamoxifen (4-OHT) resistance in estrogen receptor-positive (ER+) breast cancer cells. Currently, we tested the potential association between PRCP with breast cancer patient outcome and RTK signaling, and tumor responsiveness to endocrine therapy. We found high PRCP protein levels in ER+ breast tumors associates with worse outcome and earlier recurrence in breast cancer patients, including patients treated with TAM. We found a PRCP specific inhibitor (PRCPi) enhanced the response of ER+ PDX tumors and MCF7 tumors to endoxifen, an active metabolite of TAM in mice. We found PRCP increased IGF1R/HER3 signaling and AKT activation in ER+ breast cancer cells that was blocked by PRCPi. Thus, PRCP is an adverse prognostic marker in breast cancer and a potential target to improve endocrine therapy in ER+ breast cancers.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 28 条
[1]   HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A southwest oncology group study [J].
Arpino, G ;
Green, SJ ;
Allred, DC ;
Lew, D ;
Martino, S ;
Osborne, CK ;
Elledge, RM .
CLINICAL CANCER RESEARCH, 2004, 10 (17) :5670-5676
[2]  
Baum M, 2002, LANCET, V359, P2131
[3]   Adjuvant Hormonal Therapy for Early-Stage Breast Cancer [J].
Burstein, Harold J. ;
Griggs, Jennifer J. .
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 19 (03) :639-+
[4]   Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial [J].
Coombes, R. C. ;
Kilburn, L. S. ;
Snowdon, C. F. ;
Paridaens, R. ;
Coleman, R. E. ;
Jones, S. E. ;
Jassem, J. ;
Van de Velde, C. J. H. ;
Delozier, T. ;
Alvarez, I. ;
Del Mastro, L. ;
Ortmann, O. ;
Diedrich, K. ;
Coates, A. S. ;
Bajetta, E. ;
Holmberg, S. B. ;
Dodwell, D. ;
Mickiewicz, E. ;
Andersen, J. ;
Lonning, P. E. ;
Cocconi, G. ;
Forbes, J. ;
Castiglione, M. ;
Stuart, N. ;
Stewart, A. ;
Fallowfield, L. J. ;
Bertelli, G. ;
Hall, E. ;
Bogle, R. G. ;
Carpentieri, M. ;
Colajori, E. ;
Subar, M. ;
Ireland, E. ;
Bliss, J. M. .
LANCET, 2007, 369 (9561) :559-570
[5]   A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer [J].
De Laurentiis, M ;
Arpino, G ;
Massarelli, E ;
Ruggiero, A ;
Carlomagno, C ;
Ciardiello, F ;
Tortora, G ;
D'Agostino, D ;
Caputo, F ;
Cancello, G ;
Montagna, E ;
Malorni, L ;
Zinno, L ;
Lauria, R ;
Bianco, AR ;
De Placido, S .
CLINICAL CANCER RESEARCH, 2005, 11 (13) :4741-4748
[6]   Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity [J].
deGraffenried, LA ;
Friedrichs, WE ;
Fulcher, L ;
Fernandes, G ;
Silva, JM ;
Peralba, JM ;
Hidalgo, M .
ANNALS OF ONCOLOGY, 2003, 14 (07) :1051-1056
[7]   Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity [J].
DeGraffenried, LA ;
Friedrichs, WE ;
Russell, DH ;
Donzis, EJ ;
Middleton, AK ;
Silva, JM ;
Roth, RA ;
Hidalgo, M .
CLINICAL CANCER RESEARCH, 2004, 10 (23) :8059-8067
[8]   Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer [J].
Duan, Lei ;
Calhoun, Sarah ;
Perez, Ricardo E. ;
Macias, Virgilia ;
Mir, Fatima ;
Pergande, Melissa R. ;
Gattuso, Paolo ;
Borgia, Jeffrey A. ;
Maki, Carl G. .
CANCERS, 2022, 14 (03)
[9]   The Prolyl Peptidases PRCP/PREP Regulate IRS-1 Stability Critical for Rapamycin-induced Feedback Activation of PI3K and AKT [J].
Duan, Lei ;
Ying, Guoguang ;
Danzer, Brian ;
Perez, Ricardo E. ;
Shariat-Madar, Zia ;
Levenson, Victor V. ;
Maki, Carl G. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (31) :21694-21705
[10]   Prolylcarboxypeptidase Regulates Proliferation, Autophagy, and Resistance to 4-Hydroxytamoxifen-induced Cytotoxicity in Estrogen Receptor-positive Breast Cancer Cells [J].
Duan, Lei ;
Motchoulski, Natalia ;
Danzer, Brian ;
Davidovich, Irina ;
Shariat-Madar, Zia ;
Levenson, Victor V. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (04) :2864-2876